3113. Package # 153 (PCR. HPV - 16 genotypes)

Package No. 153 — a set of studies for diagnosing human papillomavirus (HPV) infection with 14 genotypes of high risk of developing cancer — in a quantitative format for issuing a result (the amount of virus for each genotype) and low risk (6 and 11) — in a qualitative format (i.e. whether there is a virus or not) by polymerase chain reaction (PCR). HPV types 6 and 11 manifest themselves in the body in the form of acute condylomas of the genital mucosa. High-risk types of cancer (the fourteen most recognized in the world) are the cause of the development of dysplasia, precancer and cervical cancer. In addition, these types can cause cancer of the vagina, anus, oropharynx, and penis.

This package of studies allows you to confirm or refute the presence of HPV types 6 and 11, as well as determine the concentration in the body of fourteen types of high risk of developing cancer, which will help determine the cause of changes in the skin and mucous membranes and determine additional examinations and treatment methods, control after treatment.

It is possible to prescribe a liquid-based PAP test, proliferation markers p16 and ki-67, Florocenosis with STIs.

• for differential diagnosis of HPV genotypes;
• to assess the risk of developing processes and diseases associated with HPV;
• to monitor infection caused by HPV and predict its course;
• upon detection of HPV of an unexplained genotype;
• in determining tactics, monitoring ongoing therapy and assessing the possibility of relapse after treatment.

• Scrapes from various sites depending on the test

Women